Corrigendum to “Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca2+/CaMKII pathway” [J. Pharm. Anal. 14 (2024) 435–438]
Congyu Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Jinlan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ning Sheng(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian‐Dong Jiang(Ningbo University), Haibo Yu(Guangzhou University of Chinese Medicine), Lulu Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Wu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 0
Related Papers
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
|Cancer Cell|2005|368
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients
|Signal Transduction and Targeted Therapy|2021|210
Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation
|Theranostics|2019|185
Loss of Epigenetic Control of <i>Synuclein-γ</i> Gene as a Molecular Indicator of Metastasis in a Wide Range of Human Cancers
|Cancer Research|2005|179
Extracellular Signal-Regulated Kinase–Dependent Stabilization of Hepatic Low-Density Lipoprotein Receptor mRNA by Herbal Medicine Berberine
|Arteriosclerosis Thrombosis and Vascular Biology|2005|171